… Here, we review oxaliplatin from the pharmacologic and drug … were stratified according to
the results of liver function tests (… in adult cancer patients with impaired renal function. Clin …

… NCI organ dysfunction working group • … Although the FDA has traditionally encouraged
pharmacologically guided … Patients with impaired renal and hepatic function and cancer present a …

… In our patient population low serum albumin and liver function classification as … of hepatic
impairment. A SWOG early therapeutics committee and NCI organ dysfunction working group …

… Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with
impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group …

… Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with
impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. …

… very poor and alteration of liver function is … National Cancer Institute Organ Dysfunction
Working Group conducted a phase I study on the pharmacokinetics of oxaliplatin in patients …

… are often excluded because impaired renal function might be … this study, we show that
oncology organ dysfunction studies … of the drug or pharmacologically active metabolite or is a …

… The patient with a liver function study abnormality who received … Dose-escalating and
pharmacological study of oxaliplatin in … Cancer Institute Organ Dysfunction Working Group Study. J …

… Oxaliplatin at a dose … adult cancer patients with impaired hepatic function, and there was
no recommendation on dose reduction of single oxaliplatin for patients with hepatic dysfunction […

… renal function in younger adults; however, it is a poor … , but a large impact of abnormal liver
function tests on docetaxel … A pharmacokinetic study of oxaliplatin in 25 patients between the …